M.R. Gramzinski
A5016701675- Diabetes Management and Research
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes and associated disorders
- Pharmacology and Obesity Treatment
- Cardiac Health and Mental Health
- Schizophrenia research and treatment
- Cardiovascular Health and Disease Prevention
- Chronic Disease Management Strategies
- Blood Pressure and Hypertension Studies
Milken Institute
2024-2025
George Washington University
2024-2025
Group for the Analysis of Development
2023
To evaluate whether baseline levels of depressive symptoms and diabetes-specific distress are associated with glycemic control in Glycemia Reduction Approaches Diabetes: A Comparative Effectiveness Study (GRADE), a large randomized controlled trial comparing the metabolic effects four common glucose-lowering medications when combined metformin individuals type 2 diabetes mellitus (T2DM).
OBJECTIVE To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate glycemic deterioration in adults type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS In the Glycemia Reduction Approaches Diabetes: A Comparative Effectiveness Study (GRADE), derived from mathematical modeling oral glucose tolerance tests were assessed at baseline (N = 4,712) 1, 3, 5 years following randomization to insulin glargine, glimepiride, liraglutide, or...
<p dir="ltr"><b>Objective:</b> Evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate glycemic deterioration in adults type 2 diabetes (T2D).</p><p dir="ltr"><b>Research Design Methods:</b> In the GRADE Study, derived from mathematical modeling oral glucose tolerance tests were assessed at baseline (N=4712), 1, 3, 5 years following randomization to insulin glargine, glimepiride, liraglutide, or...
<p dir="ltr"><b>Objective:</b> Evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate glycemic deterioration in adults type 2 diabetes (T2D).</p><p dir="ltr"><b>Research Design Methods:</b> In the GRADE Study, derived from mathematical modeling oral glucose tolerance tests were assessed at baseline (N=4712), 1, 3, 5 years following randomization to insulin glargine, glimepiride, liraglutide, or...
<p dir="ltr">Objectives To evaluate whether baseline levels of depressive symptoms and diabetes specific distress are associated with glycemic control in the GRADE study, a large randomized controlled trial comparing metabolic effects four common glucose-lowering medications when combined metformin individuals type 2 diabetes.</p><p dir="ltr">Methods The primary secondary outcomes were defined as an HbA1c value ≥7%, subsequently confirmed, ˃7.5%, respectively. Separate Cox...
<p dir="ltr">Objectives To evaluate whether baseline levels of depressive symptoms and diabetes specific distress are associated with glycemic control in the GRADE study, a large randomized controlled trial comparing metabolic effects four common glucose-lowering medications when combined metformin individuals type 2 diabetes.</p><p dir="ltr">Methods The primary secondary outcomes were defined as an HbA1c value ≥7%, subsequently confirmed, ˃7.5%, respectively. Separate Cox...
Objective Hypoglycemia is a major concern in type 2 diabetes (T2DM), but little known about its likelihood compared across common therapies. We the of hypoglycemia among metformin-treated patients with T2DM randomized to addition one 4 Research design & methods Randomized, controlled trial 5,047 participants <10 years’ duration, hemoglobin A1c (HbA1c) 6.8–8.5% (50.8–69.4 mmol/mol). Randomization glargine U100, glimepiride, liraglutide, or sitagliptin over 5.0 ± 1.3 (mean SD) years....